Cargando…

Selective Retina Therapy with Real-Time Feedback-Controlled Dosimetry for Treating Acute Idiopathic Central Serous Chorioretinopathy in Korean Patients

PURPOSE: To evaluate short-term treatment outcomes following selective retina therapy (SRT) with real-time feedback-controlled dosimetry in Korean patients with acute idiopathic central serous chorioretinopathy (CSC). METHODS: Sixteen eyes (16 patients) with acute idiopathic CSC (symptom duration &l...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Ye Ji, Lee, Youn Gon, Lee, Dong Won, Kim, Jae Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5818953/
https://www.ncbi.nlm.nih.gov/pubmed/29545953
http://dx.doi.org/10.1155/2018/6027871
_version_ 1783301117840457728
author Kim, Ye Ji
Lee, Youn Gon
Lee, Dong Won
Kim, Jae Hui
author_facet Kim, Ye Ji
Lee, Youn Gon
Lee, Dong Won
Kim, Jae Hui
author_sort Kim, Ye Ji
collection PubMed
description PURPOSE: To evaluate short-term treatment outcomes following selective retina therapy (SRT) with real-time feedback-controlled dosimetry in Korean patients with acute idiopathic central serous chorioretinopathy (CSC). METHODS: Sixteen eyes (16 patients) with acute idiopathic CSC (symptom duration < 3 months) were included in this retrospective study. All patients underwent a single session of SRT with real-time feedback-controlled dosimetry. Best-corrected visual acuity (BCVA) and central foveal thickness (CFT) before and 3 months after treatment were examined and compared. RESULTS: The logarithm of minimal angle of resolution BCVA was significantly better 3 months after treatment (0.16 ± 0.18) than at the time of diagnosis (0.27 ± 0.18, P = 0.002). Additionally, subretinal fluid had resolved in all 16 eyes 3 months after treatment and CFT was significantly lower 3 months after treatment (215.6 ± 17.9 μm) than at baseline (441.4 ± 124.8 μm, P < 0.001). No notable SRT-related complications were observed during the study period. CONCLUSION: The results of the present study suggest that SRT is a useful therapeutic option for patients with acute idiopathic CSC. Further studies are required to better understand the long-term efficacy of this treatment. This trial is registered with clinical trial registration number NCT03339856.
format Online
Article
Text
id pubmed-5818953
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-58189532018-03-15 Selective Retina Therapy with Real-Time Feedback-Controlled Dosimetry for Treating Acute Idiopathic Central Serous Chorioretinopathy in Korean Patients Kim, Ye Ji Lee, Youn Gon Lee, Dong Won Kim, Jae Hui J Ophthalmol Clinical Study PURPOSE: To evaluate short-term treatment outcomes following selective retina therapy (SRT) with real-time feedback-controlled dosimetry in Korean patients with acute idiopathic central serous chorioretinopathy (CSC). METHODS: Sixteen eyes (16 patients) with acute idiopathic CSC (symptom duration < 3 months) were included in this retrospective study. All patients underwent a single session of SRT with real-time feedback-controlled dosimetry. Best-corrected visual acuity (BCVA) and central foveal thickness (CFT) before and 3 months after treatment were examined and compared. RESULTS: The logarithm of minimal angle of resolution BCVA was significantly better 3 months after treatment (0.16 ± 0.18) than at the time of diagnosis (0.27 ± 0.18, P = 0.002). Additionally, subretinal fluid had resolved in all 16 eyes 3 months after treatment and CFT was significantly lower 3 months after treatment (215.6 ± 17.9 μm) than at baseline (441.4 ± 124.8 μm, P < 0.001). No notable SRT-related complications were observed during the study period. CONCLUSION: The results of the present study suggest that SRT is a useful therapeutic option for patients with acute idiopathic CSC. Further studies are required to better understand the long-term efficacy of this treatment. This trial is registered with clinical trial registration number NCT03339856. Hindawi 2018-02-06 /pmc/articles/PMC5818953/ /pubmed/29545953 http://dx.doi.org/10.1155/2018/6027871 Text en Copyright © 2018 Ye Ji Kim et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Study
Kim, Ye Ji
Lee, Youn Gon
Lee, Dong Won
Kim, Jae Hui
Selective Retina Therapy with Real-Time Feedback-Controlled Dosimetry for Treating Acute Idiopathic Central Serous Chorioretinopathy in Korean Patients
title Selective Retina Therapy with Real-Time Feedback-Controlled Dosimetry for Treating Acute Idiopathic Central Serous Chorioretinopathy in Korean Patients
title_full Selective Retina Therapy with Real-Time Feedback-Controlled Dosimetry for Treating Acute Idiopathic Central Serous Chorioretinopathy in Korean Patients
title_fullStr Selective Retina Therapy with Real-Time Feedback-Controlled Dosimetry for Treating Acute Idiopathic Central Serous Chorioretinopathy in Korean Patients
title_full_unstemmed Selective Retina Therapy with Real-Time Feedback-Controlled Dosimetry for Treating Acute Idiopathic Central Serous Chorioretinopathy in Korean Patients
title_short Selective Retina Therapy with Real-Time Feedback-Controlled Dosimetry for Treating Acute Idiopathic Central Serous Chorioretinopathy in Korean Patients
title_sort selective retina therapy with real-time feedback-controlled dosimetry for treating acute idiopathic central serous chorioretinopathy in korean patients
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5818953/
https://www.ncbi.nlm.nih.gov/pubmed/29545953
http://dx.doi.org/10.1155/2018/6027871
work_keys_str_mv AT kimyeji selectiveretinatherapywithrealtimefeedbackcontrolleddosimetryfortreatingacuteidiopathiccentralserouschorioretinopathyinkoreanpatients
AT leeyoungon selectiveretinatherapywithrealtimefeedbackcontrolleddosimetryfortreatingacuteidiopathiccentralserouschorioretinopathyinkoreanpatients
AT leedongwon selectiveretinatherapywithrealtimefeedbackcontrolleddosimetryfortreatingacuteidiopathiccentralserouschorioretinopathyinkoreanpatients
AT kimjaehui selectiveretinatherapywithrealtimefeedbackcontrolleddosimetryfortreatingacuteidiopathiccentralserouschorioretinopathyinkoreanpatients